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Secretory leukocyte protease inhibitor (SLPI) is known 
to be involved in the inhibition of inflammation, the 
modulation of immunological responses and the 
promotion of cell proliferation [1]. In cancer, increased 
SLPI expression can be detected in breast, lung, gastric 
and colorectal carcinomas.  Using antibody arrays that 
identify a panel of 350 murine and 500 human secreted 
proteins, we screened cancer cells to identify proteins 
that are highly expressed in metastatic compared to their 
non-metastatic counterparts. We found that SPLI was 
the only secreted protein increased in metastatic 
variants of both breast and colorectal cancer cells. 
Moreover, the SLPI level was associated with increased 
lung metastasis from orthotopically implanted tumors. 
These results suggest that high expression of SLPI in 
cancer cells may promote lung metastasis [2].   
Next, we checked how SLPI expression levels correlate 
with the incidence of triple negative breast cancer 
(TNBC) metastasis in patients. We analyzed SLPI 
expression in TNBC because this subgroup represents 
the most aggressive breast cancer and still has the worst 
prognosis, despite advancements in modern thera-
peutics. We found that both distant metastasis-free 
survival and overall survival were significantly worse in 
the TNBC patients who had higher SLPI expression in 
their tumors.  
If SLPI is involved in tumor growth and metastasis, 
then pharmacological repression of SLPI should inhibit 
tumor expansion and dissemination. To identify 
potential small molecule blockers of SLPI, we used 
high-throughput screening to probe a library comprised 
of 60,000 chemically-diverse compounds. Candidate 
molecules that were able to reduce the SLPI expression 
by more than 90% but were not toxic to non-malignant 
cells were then tested in our mouse model of metastasis. 
We found that pharmacological repression of SLPI 
slows the growth of primary tumors and inhibits their 
dissemination to the lung [2]. These results suggest that 
SLPI is a new target for anti-metastatic therapies for 
breast and colon cancers.  
What is a possible mechanism by which SLPI promotes 
metastasis? First, we found that SLPI physically inter-
acts with and phosphorylates retinoblastoma (Rb) tumor 
suppressor protein. To determine whether SLPI inter-
acts with Rb, we used protein extracts from two 
different cell lines and precipitated Rb complexes for 
SLPI detection. Our experiments confirmed that there is  
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a physical association between these two proteins. This 
interaction was further confirmed by the reverse 
experiment in which anti-SLPI antibody was used for 
immunoprecipitation and anti-Rb antibody was used for 
detection. For further verification of this interaction, we 
used a standard mammalian two-hybrid approach and 
our results indicate that SLPI protein directly physically 
interacted with the Rb tumor suppressor. Moreover, we 
found that treatment with recombinant SLPI protein 
increased phosphorylation of Rb. On the other hand, 
treatment with the anti-SLPI compound decreased 
phosphorylation of Rb in breast cancer cells. Interes-
tingly, it is known that phosphorylation of Rb leads to 
its release from FoxM1 binding [3] and initiates FoxM1 
transcriptional activity. Indeed, we found that over-
expression of SLPI leads to increased levels of known 
FoxM1 target proteins, such as cyclin B1, aurora kinase 
B and superoxide dismutase-2 (SOD-2). Moreover, we 
found that SLPI increases FoxM1 binding to FoxM1 
target genes (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Could SLPI overexpression cause cellular senescence 
through activation of the FoxM1? There is a body of 
literature showing that FoxM1-depletion is sufficient to 
induce cellular senescence in proliferating cells [4]. 
Activation of the FoxM1 gene suppresses reactive 
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Figure 1.  Schematic representation of SLPI effect on the
regulation  of  the  FoxM1  target  genes  and  subsequent
metastasis. SLPI activates  transcriptional  factor FoxM1, which
stimulates  expression  of  target  genes  involved  in  cell  division,
cell  migration,  premetastatic  niche  formation,  epithelial–
mesenchymal transition, senescence and metastasis.   
oxygen species (ROS) and protects cancer cells from 
senescence [5]. Thus, overexpression of SLPI might 
prevent cellular senescence in cancer cells. On the other 
hand, FoxM1also regulates c-myc expression which has 
been shown to activate cellular senescence. Therefore, 
the effects of SLPI on cellular senescence warrants 
further investigation. 
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